Science, United States
Science, United States

Time filter

Source Type

TORONTO--(BUSINESS WIRE)--Enigma Biomedical Group today announced a clinical research agreement with McGill University Research Centre for Studies in Aging in Montreal to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease. As part of the agreement, Enigma will provide funding for various research projects, and through its US entity Cerveau Technologies, Inc., will supply the MK-6240 precursor needed for the initiatives. Lee Anne Gibbs, President of Enigma Biomedical Group said, “We are proud to partner with McGill University Research Centre for Studies in Aging, one of the premier institutions in the world. This is another important step in our ongoing and long-term relationship with McGill.” Dr. Pedro Rosa-Neto, Director of McGill University Research Centre for Studies in Aging said, “These research projects will provide valuable insight into the status and progression of NFTs in healthy subjects, subjects with mild cognitive impairment and confirmed Alzheimer’s Disease. We appreciate the support of Enigma Biomedical Group and value our ongoing relationship.” Dr. Serge Gauthier, Director of the AD & Related Disorders Research Unit of the McGill University Research Center for Studies in Aging said: “The ability to visualize and quantify tau in the brain will facilitate therapeutic research in the field of Alzheimer's disease.” “At Cerveau, we are focused on providing information and technologies to researchers and clinicians to improve brain health,” said Rick Hiatt, President of Cerveau Technologies, Inc., and CEO of Enigma Biomedical Group. “We are excited by the opportunity to work with McGill and the pharmaceutical industry in providing access to this novel imaging agent to the broader scientific community." Toronto based Enigma Biomedical Group (EBG) enhances access to key technologies with a focus on molecular imaging and medicine. EBG offers a suite of services to the pharmaceutical industry and clinical research community to accelerate drug development and global access. EBG partners with academic institutions and universities to foster and broaden access to novel research. More information can be found at http://www.enigmabiomedicalgroup.com/. Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau's vision is to globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer's disease.


Note to editors: There are two photos associated with this press release. Library and Archives Canada (LAC) is honoured to be hosting members from Inuit, Métis Nation and First Nations communities to commemorate 15 years of Project Naming. The gathering is being co-organized with Carleton University from March 1 to March 3, 2017. This event is the first major community and scholarly gathering to discuss the contributions of Project Naming. The majority of individuals depicted in LAC's photographic collections are nameless. Over the last 15 years, LAC has worked with Aboriginal communities to identify names and places in these images and to rightfully preserve their history for present and future generations. The anniversary is also an opportunity for Inuit elders and youth from across Nunavut and elsewhere to celebrate the project's achievements and to foster continued engagement with First Nations, the Métis Nation and Inuit communities from across Canada. A component of this celebration will be the recording of stories and recollections from Inuit contributors to be included in a book about the history of the project being edited by Professor Carol Payne of Carleton University for McGill-Queen's University Press. "Building an honest and sharing relationship between those who record history and those who have been harmed by history takes time and trust. Library and Archives Canada is dedicated to preservation of memory and thus has a vital role to play, by making sure the past is never forgotten, and that even the difficult stories get told." Dr. Guy Berthiaume, Librarian and Archivist of Canada. ""Views from the North, which is partnered with Project Naming, include photo-based oral history interviews. For this project, students from the Inuit training program Nunavut Sivuniksavut, interview elders from their own home communities over LAC archival photographs depicting those communities decades ago. In this way, Views from the North, like Project Naming, links generations of Inuit and recasts colonial images from an Inuk perspective." Dr. Carol Payne, Associate Professor of Art History, Carleton University Before Project Naming began in 2002, the Aboriginal peoples depicted in the majority of federal archival photographs were nameless. Project Naming provides a virtual space enabling First Nations, Métis Nation and Inuit communities to access Canada's historic photo collections and engage in the identification of people and locations, thereby reconnecting with their history to share memories and stories rekindled by the photographs. The project also aims to inspire and empower Aboriginal youth with a renewed understanding and access to their past. Since Project Naming began, many individuals have reunited with their families and loved ones, and have sometimes themselves in the photographs. In December 2015, Johnny Kasudluak and his mother, Martha Kasudluak, discovered several photographs of Martha and other family members from Inukjuak, Quebec. They sent this photo of Martha with three photographs of her as a young woman: A photo of Martha Kasudluak is available at the following address: http://media3.marketwire.com/docs/johnny.jpg In September 2014, Ashevak Geetah (left) and her daughter, Eva Geetah (right) reconnected with their father and grandfather, Eetooloopak, after seeing his photo, which was taken in Iqaluit, Nunavut in March 1956 A photo of Ashevak Geetah (left) and her daughter, Eva Geetah (right) is available at the following address: http://media3.marketwire.com/docs/gar.jpg Speakers for the sessions on March 1 and 2: Moderators for the various sessions: On March 1 and 2, there will be several musical performances by students from Nunavut Sivuniksavut. The session on March 3 will look to the future of Project Naming and will host a panel of artists, including Onondaga photographer and curator Jeff Thomas, Métis artist Rosalie Favell, and Inuk filmmaker Isabella-Rose Weetaluktuk. All three use archival images in their innovative artistic practice, and will discuss the ways in which they are reclaiming and re-telling their histories and stories.


BEVERLY, Mass. and TORONTO, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today reported preliminary selected unaudited financial results for the fourth quarter and year-ended December 31, 2016. Preliminary unaudited results show that 2016 revenues increased 16% to over $10.5 million, led by the contribution from its newly acquired Embryotech Laboratories business, as well as strong growth in sales of LYKOS® clinical laser systems and increased revenues from after sale services.  Fourth quarter sales increased 37% to over $3.6 million, with net income and EBITDA expected to be over $500,000 and $750,000 respectively, a record quarter for the Company. For the year, including the effect of approximately $275,000 of one-time expenses relating to the Embryotech acquisition, the Company is expecting to report net income of approximately $650,000, and EBITDA of approximately $1.2 million. David Wolf, President and Chief Executive Officer of Hamilton Thorne Ltd. commented, “2016 was a transformational year for us as we completed a significant expansion of both our financial profile and business capabilities when we acquired Embryotech Laboratories in September.  I am pleased to report that the integration of the businesses is progressing smoothly and we are actively working on several growth initiatives brought about by marketing synergies between the Hamilton Thorne and Embryotech businesses.   Building on our internal growth initiatives and the acquisitions of the Oosight product line in 2015 and Embryotech in 2016, we remain committed to our strategy of growth through new product innovation, organic growth and acquisition.” Mr. Wolf added, “Based on continued foreign exchange headwinds as well as changes in distributor relationships in certain of our markets, we saw some challenges in our instrument business, particularly in the fourth quarter.  Gross profit margins for the year improved to over 65% as, despite some significant pricing actions to reflect currency issues, we increased sales of high-margin software, consumables and services with recurring revenues.  In order to accelerate our sales growth and get closer to our customers, we have begun to put more investment into direct sales resources in both our instrument and services businesses.” The financial information contained in this news release is based on management's estimates and is subject to adjustment. The Company expects to release its completed audited financial statements for the year ended December 31, 2016 on or about April 26, 2017. Expansion of Board of Directors The Company also announced that David Sable, portfolio manager for New York-based Special Situations Life Sciences Fund has joined the Company’s board of directors.  Dr. Sable is a reproductive endocrinologist by training and an expert in the field of human assisted reproduction.  Dr. Sable also serves on the board of directors of RESOLVE: The National Infertility Society and on the advisory board of OvaScience. All amounts are in US dollars, unless specified otherwise, and results, with the exception of EBITDA, are expressed in accordance with the International Financial Reporting Standards ("IFRS"). About Hamilton Thorne Ltd. (www.hamiltonthorne.com)   Hamilton Thorne is a leading world-wide provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as micro-surgical devices, enabling a wide array of scientific applications and In Vitro Fertilization (IVF) procedures. Its image analysis systems are designed to bring quality, efficiency and reliability to studies of reproductive cells in the human fertility, animal sciences and reproductive toxicology fields.  Hamilton Thorne’s standardized toxicology assays and quality control testing services help to improve outcomes in human IVF clinics.  Hamilton Thorne’s growing worldwide customer base consists of pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, animal breeding companies, and other commercial and academic research establishments, including Harvard, MIT, Yale, McGill, Oxford, Cambridge, the Smithsonian Institution, Charles River Labs, Covance, ABS Global, Sexing Technologies, Merck, Cook Medical, Novartis, Pfizer, and Dow Chemical. Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release. The Company has included earnings before interest, income taxes, depreciation and amortization, (“EBITDA”) as a non-IFRS measure, which is used by management as a measure of financial performance. See section entitled “Use of Non-IFRS Measures” in the Company’s Management Discussion and Analysis for the periods covered for further information. Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.


Note to editors: Two images are included with this press release on Marketwired's website. To mark the 15th anniversary of Project Naming, Library and Archives Canada (LAC), in collaboration with Carleton University, will host a gathering of community members, Aboriginal leaders and scholars for this remarkable initiative. This free public event will be the first major community and scholarly gathering to discuss the contribution of Project Naming to Canada's Aboriginal history. The majority of individuals from the North depicted in LAC's photographic collections are nameless. Over the last 15 years, LAC has worked with Aboriginal communities to identify names and places in these images to rightfully preserve their history for present and future generations. This gathering will also provide an opportunity for Inuit elders and youth from across Nunavut and elsewhere to celebrate the project's achievements and to look to the future. Another component of this event will be the recording of stories and recollections from Inuit contributors to be included in a book about the history of the project being edited by Professor Carol Payne of Carleton University for McGill-Queen's University Press. Follow us on Twitter (@LibraryArchives), Facebook, Flickr and YouTube. Before Project Naming began in 2002, the Aboriginal peoples depicted in the majority of federal archival photographs were nameless. Project Naming provides a virtual space enabling First Nations, Métis Nation and Inuit communities to access Canada's historic photo collections and engage in the identification of people and locations, thereby reconnecting with their history to share memories and stories rekindled by the photographs. The project also aims to inspire and empower Aboriginal youth with a renewed understanding and access to their past. Since Project Naming began, many individuals have reunited with their families and loved ones, and have sometimes found themselves in the photographs. In December 2015, Johnny Kasudluak and his mother, Martha Kasudluak, discovered several photographs of Martha and other family members from Inukjuak, Quebec. They sent this photo of Martha with three photographs of her as a young woman. A photo of Johnny Kasudluak is available at the following address: http://media3.marketwire.com/docs/1087066_Johnny_Kasudluak.jpg In September 2014, Ashevak Geetah (left) and her daughter, Eva Geetah (right) reconnected with their father and grandfather, Eetooloopak, after seeing his photo, which was taken in Iqaluit, Nunavut in March 1956. A photo of Ashevak Geetah (left) and her daughter, Eva Geetah (right) is available at the following address: http://media3.marketwire.com/docs/1087066_Gar_Lunney.jpg


BEVERLY, Mass. and TORONTO, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today reported preliminary selected unaudited financial results for the fourth quarter and year-ended December 31, 2016. Preliminary unaudited results show that 2016 revenues increased 16% to over $10.5 million, led by the contribution from its newly acquired Embryotech Laboratories business, as well as strong growth in sales of LYKOS® clinical laser systems and increased revenues from after sale services.  Fourth quarter sales increased 37% to over $3.6 million, with net income and EBITDA expected to be over $500,000 and $750,000 respectively, a record quarter for the Company. For the year, including the effect of approximately $275,000 of one-time expenses relating to the Embryotech acquisition, the Company is expecting to report net income of approximately $650,000, and EBITDA of approximately $1.2 million. David Wolf, President and Chief Executive Officer of Hamilton Thorne Ltd. commented, “2016 was a transformational year for us as we completed a significant expansion of both our financial profile and business capabilities when we acquired Embryotech Laboratories in September.  I am pleased to report that the integration of the businesses is progressing smoothly and we are actively working on several growth initiatives brought about by marketing synergies between the Hamilton Thorne and Embryotech businesses.   Building on our internal growth initiatives and the acquisitions of the Oosight product line in 2015 and Embryotech in 2016, we remain committed to our strategy of growth through new product innovation, organic growth and acquisition.” Mr. Wolf added, “Based on continued foreign exchange headwinds as well as changes in distributor relationships in certain of our markets, we saw some challenges in our instrument business, particularly in the fourth quarter.  Gross profit margins for the year improved to over 65% as, despite some significant pricing actions to reflect currency issues, we increased sales of high-margin software, consumables and services with recurring revenues.  In order to accelerate our sales growth and get closer to our customers, we have begun to put more investment into direct sales resources in both our instrument and services businesses.” The financial information contained in this news release is based on management's estimates and is subject to adjustment. The Company expects to release its completed audited financial statements for the year ended December 31, 2016 on or about April 26, 2017. Expansion of Board of Directors The Company also announced that David Sable, portfolio manager for New York-based Special Situations Life Sciences Fund has joined the Company’s board of directors.  Dr. Sable is a reproductive endocrinologist by training and an expert in the field of human assisted reproduction.  Dr. Sable also serves on the board of directors of RESOLVE: The National Infertility Society and on the advisory board of OvaScience. All amounts are in US dollars, unless specified otherwise, and results, with the exception of EBITDA, are expressed in accordance with the International Financial Reporting Standards ("IFRS"). About Hamilton Thorne Ltd. (www.hamiltonthorne.com)   Hamilton Thorne is a leading world-wide provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as micro-surgical devices, enabling a wide array of scientific applications and In Vitro Fertilization (IVF) procedures. Its image analysis systems are designed to bring quality, efficiency and reliability to studies of reproductive cells in the human fertility, animal sciences and reproductive toxicology fields.  Hamilton Thorne’s standardized toxicology assays and quality control testing services help to improve outcomes in human IVF clinics.  Hamilton Thorne’s growing worldwide customer base consists of pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, animal breeding companies, and other commercial and academic research establishments, including Harvard, MIT, Yale, McGill, Oxford, Cambridge, the Smithsonian Institution, Charles River Labs, Covance, ABS Global, Sexing Technologies, Merck, Cook Medical, Novartis, Pfizer, and Dow Chemical. Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release. The Company has included earnings before interest, income taxes, depreciation and amortization, (“EBITDA”) as a non-IFRS measure, which is used by management as a measure of financial performance. See section entitled “Use of Non-IFRS Measures” in the Company’s Management Discussion and Analysis for the periods covered for further information. Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.


BEVERLY, Mass. and TORONTO, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART) and developmental biology research markets, today reported preliminary selected unaudited financial results for the fourth quarter and year-ended December 31, 2016. Preliminary unaudited results show that 2016 revenues increased 16% to over $10.5 million, led by the contribution from its newly acquired Embryotech Laboratories business, as well as strong growth in sales of LYKOS® clinical laser systems and increased revenues from after sale services.  Fourth quarter sales increased 37% to over $3.6 million, with net income and EBITDA expected to be over $500,000 and $750,000 respectively, a record quarter for the Company. For the year, including the effect of approximately $275,000 of one-time expenses relating to the Embryotech acquisition, the Company is expecting to report net income of approximately $650,000, and EBITDA of approximately $1.2 million. David Wolf, President and Chief Executive Officer of Hamilton Thorne Ltd. commented, “2016 was a transformational year for us as we completed a significant expansion of both our financial profile and business capabilities when we acquired Embryotech Laboratories in September.  I am pleased to report that the integration of the businesses is progressing smoothly and we are actively working on several growth initiatives brought about by marketing synergies between the Hamilton Thorne and Embryotech businesses.   Building on our internal growth initiatives and the acquisitions of the Oosight product line in 2015 and Embryotech in 2016, we remain committed to our strategy of growth through new product innovation, organic growth and acquisition.” Mr. Wolf added, “Based on continued foreign exchange headwinds as well as changes in distributor relationships in certain of our markets, we saw some challenges in our instrument business, particularly in the fourth quarter.  Gross profit margins for the year improved to over 65% as, despite some significant pricing actions to reflect currency issues, we increased sales of high-margin software, consumables and services with recurring revenues.  In order to accelerate our sales growth and get closer to our customers, we have begun to put more investment into direct sales resources in both our instrument and services businesses.” The financial information contained in this news release is based on management's estimates and is subject to adjustment. The Company expects to release its completed audited financial statements for the year ended December 31, 2016 on or about April 26, 2017. Expansion of Board of Directors The Company also announced that David Sable, portfolio manager for New York-based Special Situations Life Sciences Fund has joined the Company’s board of directors.  Dr. Sable is a reproductive endocrinologist by training and an expert in the field of human assisted reproduction.  Dr. Sable also serves on the board of directors of RESOLVE: The National Infertility Society and on the advisory board of OvaScience. All amounts are in US dollars, unless specified otherwise, and results, with the exception of EBITDA, are expressed in accordance with the International Financial Reporting Standards ("IFRS"). About Hamilton Thorne Ltd. (www.hamiltonthorne.com)   Hamilton Thorne is a leading world-wide provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART) and developmental biology research markets. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as micro-surgical devices, enabling a wide array of scientific applications and In Vitro Fertilization (IVF) procedures. Its image analysis systems are designed to bring quality, efficiency and reliability to studies of reproductive cells in the human fertility, animal sciences and reproductive toxicology fields.  Hamilton Thorne’s standardized toxicology assays and quality control testing services help to improve outcomes in human IVF clinics.  Hamilton Thorne’s growing worldwide customer base consists of pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, animal breeding companies, and other commercial and academic research establishments, including Harvard, MIT, Yale, McGill, Oxford, Cambridge, the Smithsonian Institution, Charles River Labs, Covance, ABS Global, Sexing Technologies, Merck, Cook Medical, Novartis, Pfizer, and Dow Chemical. Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release. The Company has included earnings before interest, income taxes, depreciation and amortization, (“EBITDA”) as a non-IFRS measure, which is used by management as a measure of financial performance. See section entitled “Use of Non-IFRS Measures” in the Company’s Management Discussion and Analysis for the periods covered for further information. Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.


OTTAWA, QUÉBEC--(Marketwired - 1 mars 2017) - Bibliothèque et Archives Canada Note aux rédacteurs : Deux photos sont associées à ce communiqué de presse. Bibliothèque et Archives Canada est honoré d'accueillir des membres de communautés inuites, de la Nation métisse et des Premières Nations pour célébrer les 15 ans du projet Un visage, un nom. Cette grande rencontre, organisée en collaboration avec l'Université Carleton, se tiendra du 1er au 3 mars 2017. C'est la première fois que des universitaires et des représentants de communautés autochtones se réunissent en si grand nombre pour discuter du projet Un visage, un nom. La plupart des personnes apparaissant sur les archives photographiques de BAC ne sont pas identifiées. Au cours des 15 dernières années, BAC a travaillé de concert avec des collectivités autochtones afin d'identifier des gens et des lieux photographiés, le tout dans le but de préserver comme il se doit leur histoire pour les générations présentes et futures. La rencontre réunira aussi des aînés et des jeunes inuits du Nunavut et d'ailleurs qui témoigneront des réussites du projet. Ce sera également l'occasion de réitérer l'importance de poursuivre le travail avec les communautés inuites, la Nation métisse et les Premières Nations. On profitera de ce rassemblement pour enregistrer les récits et les souvenirs de participants inuits afin de les inclure dans un livre portant sur l'histoire d'Un visage, un nom. L'ouvrage sera édité par la professeure Carol Payne de l'Université Carleton pour le compte des Presses universitaires McGill-Queen's. « Un visage, un nom est l'un des plus importants projets de Bibliothèque et Archives Canada. Je suis très fier de ce que nous avons accompli, et je sais que tous ensemble, nous pouvons aller encore plus loin. Il faut du temps et de la confiance pour bâtir une relation d'honnêteté et de partage entre ceux qui consignent l'histoire et ceux qui ont été blessés par l'histoire. En tant qu'organisation vouée à la préservation de la mémoire, nous avons un rôle primordial à jouer à cet égard. » - Guy Berthiaume, bibliothécaire et archiviste du Canada « Le projet Views from the North joint ses efforts à Un visage, un nom en recueillant des histoires orales auprès d'aînés du Nunavut. Dans le cadre de ce projet, des étudiants du programme Nunavut Sivuniksavut interviewent des aînés de leur communauté, à qui ils montrent des photos de Bibliothèque et Archives Canada portant sur ces communautés. Views from the North crée ainsi des liens entre différentes générations d'Inuits et leur permet de comprendre ces images selon le point de vue d'un Inuit. » - Carol Payne, professeure agrégée en histoire de l'art, Université Carleton Avant le lancement d'Un visage, un nom, en 2002, les Autochtones apparaissant sur la majorité des photos d'archives fédérales n'étaient pas identifiés. Le projet Un visage, un nom veut remédier à la situation : il offre aux communautés inuites, aux Premières Nations et à la Nation métisse un espace virtuel où elles peuvent voir des photos d'archives et aider à y identifier des personnes et des lieux, tout en renouant avec leur histoire et en partageant les souvenirs rattachés à ces photos. Un visage, un nom veut aussi aider les jeunes Autochtones à mieux comprendre leur passé pour s'en inspirer et se réapproprier leur histoire. Depuis le début du projet, plusieurs participants ont pu retrouver des êtres chers; certains se sont même reconnus sur des photos. Ainsi, en décembre 2015, Johnny Kasudluak et sa mère Martha ont découvert plusieurs photos de celle-ci et d'autres membres de la famille, originaire d'Inukjuak, au Québec. Ils nous ont fait parvenir cette photo de Martha posant avec trois photos d'elle prises alors qu'elle était une jeune fille. Une photo de Martha Kasudluak est disponible à cette adresse : http://media3.marketwire.com/docs/johnny.jpg En septembre 2014, Ashevak Geetah (à gauche) et sa fille Eva (à droite) ont renoué avec Eetooloopak, leur père et grand-père, après avoir vu cette photo de lui, prise en mars 1956 à Iqaluit, au Nunavut. Une photo d'Ashevak Geetah (à gauche) et sa fille Eva (à droite) est disponible à cette adresse : http://media3.marketwire.com/docs/gar.jpg Conférenciers du 1er et du 2 mars : Les 1er et 2 mars, des étudiants du programme Nunavut Sivuniksavut offriront des prestations musicales. La séance du 3 mars s'intéressera à l'avenir d'Un visage, un nom et accueillera un panel d'artistes composé du photographe et conservateur onondaga Jeff Thomas, de l'artiste métisse Rosalie Favell et de la cinéaste inuite Isabella-Rose Weetaluktuk. Tous les trois intègrent de façon originale des photos d'archives à leur travail artistique; ils expliqueront comment ils s'approprient et font revivre leur histoire.


News Article | January 27, 2017
Site: www.techtimes.com

Starting schools later could help teenagers from Canada benefit from better sleep. This could translate in a better chance for success among this category of children, according to new research. The study, published, Jan. 24, in the Journal of Sleep Research, by researchers from McGill University, addresses the issue of insufficient sleep and its associated harms. The scientists discovered that students who are enrolled in schools that start earlier sleep less, thus being less likely to meet the national sleep recommendations for their ages. "Students slept an average of 8:36 h on weekdays and 69% met sleep duration recommendations, but 60% reported feeling tired in the morning. Every 10-min delay in school start time corresponded with 3.2 additional minutes of sleep, a 1.6% greater probability of sufficient sleep and a 2.1% smaller probability of feeling tired at school in the morning," noted the research. This means that these students are more likely to be tired in the morning. According to the research, one in three students don't get enough sleep for their age, and there is a scientific explanation for this phenomenon. "As teenagers go through puberty, their circadian clock gets delayed by two to three hours. By the time they reach junior high, falling asleep before 11 p.m. becomes biologically difficult, and waking up before 8 a.m. is a struggle. Adolescents are fighting biology to get to school on time," noted lead author Geneviève Gariépy, a post-doctoral student at McGill's Institute of Health and Social Policy. Prior research showed that sleep-deprived teenagers perform worse in school. They are prone to developing more health issues and are also vulnerable to conditions such as anxiety, depression, and behavioral problems. The current research employed data from 30,000 students, part of 362 schools across Canada. The data was gathered from a cross-national survey, carried out once every four years, in more than 40 countries. After assessing the number of sleeping hours that children in this age group make, the researchers then investigated the school programs of the 362 institutions, whose first class ranged from 8:00 to 9:30. After a cross-examination of the data, a strong causality was found between the class starting late and the better performance and well-being of the students. However, teenagers in Canada are not the only ones to have sleeping problems in both the patterns and the quantity of their night's sleep. According to the United States National Sleep Foundation, most of the teenagers in the United States also don't get enough sleep. "Teens need about 8 to 10 hours of sleep each night to function best. Most teens do not get enough sleep - one study found that only 15% reported sleeping 8 1/2 hours on school nights. Teens tend to have irregular sleep patterns across the week - they typically stay up late and sleep in late on the weekends, which can affect their biological clocks and hurt the quality of their sleep," noted the foundation's data. © 2017 Tech Times, All rights reserved. Do not reproduce without permission.


News Article | February 27, 2017
Site: news.yahoo.com

NEW ORLEANS (AP) — It's too soon to discuss whether new safety rules will be established after a man accused of driving drunk plowed into a Mardi Gras parade crowd, a New Orleans police spokesman said Monday. "It's probably a little premature," Michael "Beau" Tidwell said. "We're working now to make sure everything was handled correctly and victims were well taken care of." He said he's also trying to track down why a police report puts the number of people hit at 32. Earlier statements had the number at 28, with 21 taken to hospitals and seven declining treatment. The accident occurred Saturday night during one of the season's glitziest parades. The Krewe of Endymion travels a route more than 5 miles long, most of it on four-lane streets divided by a wide median. Thousands of people throng the sidewalks and medians to watch the elaborate floats and clamor to catch beads and trinkets tossed by riders. Those in the median are facing away from the side of the street that remains open for traffic. A pickup truck hit two other vehicles on that side of the street, then wound up in the median, police said. Those injured include police Lt. Michelle Woodfork, niece of former Police Superintendent Warren Woodfork, Tidwell said. The current superintendent, Michael Harrison, said earlier that she was on parade duty. Driver Neilson Rizzuto, 25, is jailed, his bond set at $125,000 on charges of first-degree negligent vehicular injuring, hit-and-run driving causing serious injury and reckless driving. Police have said a breath test showed a blood alcohol level nearly triple the level considered legal proof of intoxication. At least three victims remained hospitalized overnight with moderate to serious injuries, police said Sunday. There were no fatalities. Ages of the victims ranged from 1 to patients in their 50s, police said. Tidwell said health privacy rules meant that he could not give more detailed information about the victims or update their conditions. Asked by reporters Saturday night whether police suspected terrorism, Superintendent Harrison said, "We suspect that that subject was highly intoxicated." Rizzuto is being held on $125,000 bond in a New Orleans jail, online records show. Commissioner Robert Blackburn said if Rizzuto makes bond he would be placed under house arrest, required to wear an ankle monitor and forbidden from driving, The Advocate reported (http://bit.ly/2mtjUnG). The commissioner told Rizzuto, who was handcuffed and wearing an orange jumper, that he was setting the bail for an amount he "envisioned" for about 21 counts — referring to the number of people who went to the hospital. Rizzuto's father told WWL-TV (http://bit.ly/2lZWmcs) that he was still trying to understand what happened and that his son is a "good kid." John Rizzuto told the station he spoke with his son multiple times Sunday morning and that his son said "a stranger gave him a drink off the street and that's the last thing he remembered." Saturday night's parade was put on by the Krewe of Endymion, which is known for its long, elaborate floats and the big party it hosts at the Superdome after the parade. Associated Press writer Kevin McGill contributed to this report.


News Article | February 23, 2017
Site: www.marketwired.com

MONTRÉAL, QUÉBEC--(Marketwired - 23 fév. 2017) - Thérapeutique Knight inc. (TSX:GUD) (« Knight ») a annoncé aujourd'hui (i) la démission de Ed Schutter et (ii) la nomination de Dre. Sarit Assouline au conseil d'administration de Knight. « Je remercie Ed pour sa contribution remarquable à Knight depuis qu'il avait joint nos rangs début 2015, a déclaré Jonathan Ross Goodman, chef de la direction de Knight. Nous accueillons, pour le remplacer dans notre équipe de direction, Dre. Sarit Assouline, hématologue à l'Hôpital général juif et professeure associée de médecine et d'oncologie à l'Université McGill. Dre. Assouline est une clinicienne qui a de nombreuses publications à son actif; c'est un ajout à la diligence scientifique de Knight, au moment où nous obtenons des licences pour des médicaments innovants qui améliorent la vie des patients ». Après sa formation à l'Université McGill en hématologie et en oncologie, Dre. Assouline a complété un programme de maîtrise en épidémiologie clinique et en biostatistique à l'Université McGill, à titre de boursière de recherche IRSC sur le développement de médicaments au Groupe d'essais cliniques de l'Institut national du cancer du Canada. Depuis 2005, elle a participé à la conception et à la direction de nombreux essais cliniques de thérapies novatrices pour les patients atteints de leucémie et de lymphome, notamment des thérapies à anticorps monoclonaux, des inhibiteurs de protéasome, des inhibiteurs d'histone-désacétylase et des médicaments ciblant la conversion de protéines. Dre. Assouline est directrice de la Clinique de leucémie myéloïde chronique de l'Hôpital général juif; à ce titre, elle a contribué à des recherches épidémiologiques sur les résultats de patients traités par inhibiteurs de la tyrosine-kinase. Thérapeutique Knight inc., établie à Montréal, au Canada, est une société pharmaceutique spécialisée qui concentre ses efforts sur l'acquisition ou l'obtention sous licence de droits de distribution de produits pharmaceutiques novateurs destinés aux marchés canadien et internationaux distinctifs. Les actions de Knight se négocient à la TSX sous le symbole « GUD ». Pour plus de renseignements concernant Thérapeutique Knight inc., consultez son site Web au www.gud-knight.com ou www.sedar.com. Le présent document peut contenir des énoncés prospectifs et des prévisions de Thérapeutique Knight inc. et ses filiales. Ces énoncés prospectifs, de par leur nature, comportent nécessairement des risques et des incertitudes susceptibles de faire en sorte que les résultats réels diffèrent sensiblement de ceux envisagés par ces énoncés prospectifs. Thérapeutique Knight inc. considère que les hypothèses sur lesquelles reposent ces énoncés prospectifs sont réputées raisonnables à la date de leur formulation, mais elle avertit le lecteur que ces hypothèses sur des événements à venir, dont bon nombre sont indépendants de la volonté de Thérapeutique Knight inc. et de ses filiales, pourraient se révéler incorrectes. Les facteurs et les risques susceptibles de faire en sorte que les résultats réels diffèrent sensiblement des résultats prévus font l'objet d'une discussion dans le rapport annuel de Thérapeutique Knight inc. et dans la notice annuelle de Thérapeutique Knight inc. pour l'exercice clos le 31 décembre 2015. Thérapeutique Knight inc. rejette toute intention ou obligation d'actualiser ou de réviser tout énoncé prospectif, que ce soit en réponse à de nouveaux renseignements ou à des événements à venir, sauf si la loi l'exige.

Loading McGill collaborators
Loading McGill collaborators